728934-83-6

Basic information

• Product Name: Benzaldehyde, 3-[(5-chloro-2-pyridinyl)oxy]-
• CAS NO: 728934-83-6
• Molecular Formula: C12H8ClNO2
• Molecular Weight: 233.654
• Mol File: 728934-83-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 3-[(5-chloro-2-pyridinyl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 3-[(5-chloro-2-pyridinyl)oxy]-(728934-83-6)
• EPA Substance Registry System: Benzaldehyde, 3-[(5-chloro-2-pyridinyl)oxy]-(728934-83-6)

Safety Data

• Hazardous Substances Data: 728934-83-6(Hazardous Substances Data)

Upstream product

• 16110-09-1 2,5 dichloropyridine 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 1191250-61-9 {3-[(5-chloropyridin-2-yl)oxy]phenyl}methanol 
• 1191250-56-2 2-[3-(bromomethyl)phenoxy]-5-chloropyridine 
• 1191250-62-0 diethyl {3-[(5-chloropyridin-2-yl)oxy]benzyl}phosphonate 
• 1191286-53-9 (4E)-4-{3-[(5-chloropyridin-2-yl)oxy]benzylidene}-3-methyl-N-(pyridin-3-yl)piperidine-1-carboxamide 

Relevant articles and documents

4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS

The present invention relates to compounds of Formula (I), wherein Ar is optionally substituted phenyl or heteroaryl and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM

Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH2- or -C(O)-; Z is -CHR12- or a valence bond; Y is -CH2-, -C(O)-, CH(OR13)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- -and Y is -CH2-, -C(O)- or -CH(OR10)- (in formula II) or -CH- (in formula I); R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, benzyloxy or a group of formula (IIIa). R1 is H, CN, halogen, -CONH2, -COOR15, CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 or, in case the compound is of formula (II) wherein the optional double bond exists or in case R2 or R3 is benzyloxy or a group of formula (IIIa) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R1 can also be -NO2 or NR16R17; R4 is H, -NO2, CN, halogen, -CONH2, -COOR15, -CH2NR15R18, -NR16R17, NHC(O)R5 or -NHC(NH)NHCH3; R5 is alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxyalkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHR6NR,R8 or one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.